About Us
Innocoll is a privately held international biopharmaceutical company focused on targeted drug delivery primarily in the areas of biodegradable surgical implants and topically applied healthcare products.
We develop and manufacture a range of pharmaceutical products and medical devices using our proprietary collagen-based technologies, CollaRX®, CollaFilm™, CollaPress™ and LiquiColl®. Our technologies are well established and are fully biocompatible and biodegradable with a long history of safe and effective use.
We have commercial products on the market in Europe, the US, and many other ROW countries. We also have a broad portfolio of pipeline products at advanced stages of clinical development.
Other products in clinical and regulatory development include: Gentamicin Surgical Implant in phase 3 for the prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and XaraColl in phase 3 for the management of post-operative pain.